Colorado-based global medical nutrition company PanTheryx Inc and Dr. Reddy’s Laboratories Ltd. on Wednesday announced an agreement under which the Hyderabad pharma firm gets exclusive right to market and distribute the former’s product in several countries.
Under the pact, Dr. Reddy’s will market and distribute PanTheryx’s nutritional intervention DiaResQ for infectious diarrhoea in India and Nepal, under the Reliqua brand. Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets are other places where Dr. Reddy’s gets to market and distribute the product, a release said.
Boosts immunity
DiaResQ, recognised in Reimagining Global Health as a leading healthcare innovation with great promise to transform global health by 2030, helps promote intestinal repair and boost natural immune defences, leading to restoration of normal digestive function, the release said.
“This agreement covers some of the largest and most promising markets throughout the world for PanTheryx and its products,” PanTheryx president and CEO, Mark A. Braman, said.
Dr. Reddy’s co-chairman and CEO G.V. Prasad said, “By adding Reliqua to our existing portfolio of gastrointestinal brands, Dr. Reddy’s can provide an important new tool for healthcare practitioners across many markets.”
